Investor Presentation

May 2024

Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by representatives of Venus Medtech(Hangzhou) Inv. (the " Company") for use in presentation by the company at investor meetings for information purposes. No part of this presentation should form the basis of , or be relied on in connection with, any contract or commitment or investment decision whatsoever.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives shall have any responsibility or liability whatsoever(for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially.

This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives is under an obligation to update, revise or affirm.

The information communicated in this presentation contains certain statements that are or may be forwarding-looking. These statements typically contain words such as "will""may""expert""forecast""plan "and "anticipate "and words of similar import. By their nature forward-looking statement involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not rely on these forward –looking statements. The Company assumes no responsibility to update the forward-looking statements or to adapt them to future events or developments.

This presentation and the information contained herein does not constitute or form part of any offer to sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company in any jurisdiction. This presentation and the information contained herein is highly confidential and being furnished to you solely for your information and may not be reproduced or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or in the United States, Canada, Australia, Japan, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will be accepted.

By attending this presentation, you acknowledge that you will be solely responsible for you own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Any decision to purchase securities in the context of a proposed offering of securities, if any, should be made solely on the basis of information contained in an offering circular or prospectus prepared in relation to such offering.

By reviewing this presentation, you are deemed to have represented and agreed that you and any customers you represent are neither(i) a "qualified institutional buyer"(within the meaning of Rule 14A under the United States Securities Act of 1933, as amended), or(ii) outside the Unites States. Yor re also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance(Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.

01 Global Expansion

02 R&D Innovation

03 Future Prospects

01 Global Expansion

“Intelligently Manufactured in China” Valve Products Go Global

Comprehensive Solutions for Structural Heart Disease

- All series of “China Intelligently Manufactured " valves have been introduced to more than 50 countries and regions worldwide, including Asia, Europe, South America
- A complete product pipeline covering all four heart valves, namely TAVR, TPVR, TMVR and TTVR, as well as hypertrophic cardiomyopathy, hypertensive renal denervation (RDN) therapy and relevant accessory products

860+
Employees

850+
Patent applications

> ¥ 200 m
Invested in R&D per year

16000+
Real-world implantation cases

11 years
The longest duration of follow-up

550+
Centers nationwide

99.43%
Proportion of immediate safe surgery

Sales Revenue Continued to Grow, Overseas Business Performed Strongly

Sales Revenue

Unit: Million RMB



Revenue in China

Unit: Million RMB



Overseas Revenue

Unit: Million RMB

Sales Proportion reach 15%



Globalization Strategy

01 Advance diligently in the field of structural heart disease to address clinical pain points with ground-breaking innovations

02 Three R&D centers in China, the U. S. and Israel to ensure continuous innovation transformation

03 Comprehensive global IP portfolio spanning across China, the U.S., Europe etc.

04 Excellent global clinical and registration capability, bolstering efforts to expand global presence

05 Rigorous production and quality management systems aligned with global standards from the U.S., the EU, and China

06 Global professional sales & marketing teams, supported by a robust international supply chain system

International IP Layout and Global Marketing

IP Portfolio

Leading in IP Quality and Quantity

- As of April 30, , a total of 863 patents and patents under applications, including 707 invention patents, of which 432 are authorized invention patents
- IP covers China, U.S., Europe etc., of which 80% are invention patents

In-depth Protection in Key Technology

- Detailed IP protection in key technology such as latest dry-tissue, balloon expandable valve, anti-PVL technology

Comprehensive Risk Management

- dynamic and in-depth assessment and analysis management of business risks related to intellectual property In the whole life cycle of products



Global Sales Localization

Appointed Shakeel Osman as the head of the International Congenital Heart Disease Department and leading the pulmonary valve business globally (except Chinese mainland)

Global Quality Management System Continuously Improve Production Efficiency





Core Product

VenusP-Valve

Transcatheter pulmonary valve replacement （TPVR）

VenusP-Valve: Global Business Grow Steadily

Approved	EU	China	Australia	Canada
Ongoing	Kazakhstan	Singapore		
Clinical Trial	U.S.	Japan	Japan-US Harmonization by Doing	



Global Sales	Country/District of entry	Commercial Sales in Europe	Pivotal Clinical Study Implantation	The longest clinical follow-up
1100+	56+	675+	136	10+ Years

VenusP-Valve: Recognized by Mainstream Markets

TOP 5 Countries by Sales since 2022



VenusP-Valve: Clinical Study in the U.S. about to Begin

The First China-made Valve Product Obtained Approval from FDA for IDE Study

- Obtained FDA Investigational Device Exemption (IDE) approval in July 2023 and pivotal clinical study about to initiate
- The clinical study is expected to enroll 60 patients In U.S. and Japan

First self-expanding pulmonary valve approved in Europe

Easier deployment, less procedure time



Various specifications available

Meet the needs of 85% patients

Six radiopaque markers

Precise valve position

Strong anchoring capabilities

Stable and safer

Wide Market of TPVR

Global

Global TPVR procedures and penetration rate during 2018-2025 continues to increase

CAGR 2018-2021 3-years **16.82%**



China

Target patients number for TPVR in China was 28 thousand in 2021 and is estimated to reach 41 thousand in 2025



来源 1.2012-2020年中国心外科手术和体外循环数据白皮书
2.新视界2022-2025年中国TPVR行业市场专题研究及重点企业调研报告
3.经导管肺动脉瓣置换术的新器械与新技术进展

Core Product

VenusA Series

Transcatheter Aortic Valve Replacement（TAVR）

TAVR in China： Profitability Strategy Paid off

VenusA series Performance in 2023

4300
Implantations

70%+
2nd Gen proportion

550+
Hospital coverage

220人
Sales person

The Only TAVR company in China that achieved positive commercial profit

Market Share Continues to be No.1



Procedures in a single month in 2023 hit a record high

Commercial Profitability Improved

2023 Achieved about 47 million RMB Commercial Profit



Access for TAVR Promoted

TAVR Medical Insurance Coverage Continued to Increase in 2023



Note: the map contains medical insurance information that are not publicly disclosed and only for reference.

02 R&D Innovation

Product Pipeline

	Products		Pre Clinical / Clinical Trials / Registration / Marketed
Aortic Valve	TAVR	VenusA series	Approved in 10 countries including China, Asia-Pacific and Latin America
		Venus-Vitae	Preparing Pivotal Study → Approved in Argentina and Chile
		Venus-PowerX	Preparing Pivotal Study → Approved in Argentina and Chile
		Valve for regurgitation	Animal Study
Pulmonary Valve	TPVR	VenusP-Valve	Approved in 56 European, Asia-Pacific and South American countries; Preparing US Pivotal study
Mitral Valve	TMVR	Cardiovalve	EFS
Tricuspid Valve	TTVR	Cardiovalve	Pivotal Study
Structural Heart Platform Technology	PIMSRA	Liwen RF	Completed Enrollment of Pivotal Study
	RDN	Echomplish Platform	Animal Study
Accessories	3nd generation catheter sheath	G Sheath	Approved in China
	Balloon expandable sheath	TAV0	Approved in China

Global progress

China progress

Venus-Vitae

Feature & Clinical Progress

- Balloon-expandable valve design
- Anti-calcification treated dry-tissue powered by Venus Endura
- Patented lock-wire technology
- Steerable control, Commissures alignment, Coaxial rotation
- Adaptive active annular sealing technology
- Approved in Argentina in Dec 2022
- Approved in Chile in Oct 2023

Venus-Vitae Argentina FIM Study Summary

Significant Improvement of Hemodynamic Performance



Figure 2. significant improvement in AV peak velocity (A), AV mean gradient (B), AV area (C) and LVEF (D) at 6-month follow-up. Error bars represent 95% CI. AV=aortic valve, LVEF=left ventricular ejection fraction.

Significant Improvement of Heart Function



Figure 3. significant improvement in NYHA class heart function at 6-month follow-up. NYHA=New York Heart Association.

Occurrence of Averse Events Post-procedure

Table 3. Occurrence of Averse Events Post-procedure (N=7)

	Baseline	Pre-discharge	1 Month	6 Months
Mortaliy	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)
Strok	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)
Heart failure re-hospitalization	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)
Reintervention	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)
Acute kidney injury	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)
Major bleeding	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)
Major vascular/access/cardiac structure related complication	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)
Moderate or greater aortic regurgitation	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)
PPMI	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)
LBBB	0.0% (0)	0.0% (0)	0.0% (0)	0.0% (0)

PPMI=Permanent Pacemaker Implantation,
LBBB=Left Bundle Branch Block.

- Procedural Technical Success: **100%**
- **No** Death, **No** Stroke and **No** Reintervention
- Significant Improvement of Hemodynamic Performance

Venus-Vitae Global Strategy

Global Clinical & Registration Strategy

- Global pivotal clinical study is expected to begin in 2H2024
- Support both CE Mark and China NMPA approval

Vitae Global

- **Europe ≈60%**
- **China ≈40%**

Global Enrollment 150

Venus-PowerX

Feature & Clinical Progress

- Self-expanding TAVR
- Anti-calcification treated dry-tissue powered by Venus Endura
- Pre-mounted, less preoperative loading time
- Active anti-PVL technology
- Fully-released, 100% retrievable
- EFS completed and in follow-up status
- Approved in Argentina in May 2023
- Approved in Chile in Oct 2023

Venus-PowerX FIM Clinical Results

- No all-cause mortality, all-cause stroke, or valve reintervention
- VARC-3 technical success at exit from operation room： 95.8%
- VARC-3 device success at 30 days： 87%

	Overall (n = 24)
Procedural variables	
Transfemoral access	24 (100.0)
Pre-dilatation	20 (83.3)
Post-dilatation	10 (41.7)
Recapture at partial deployment	8 (33.3)
Recapture at 100% full deployment	2 (8.3)
VARC-3 technical success [a]	23 (95.8)
Successful implantation	24 (100.0)
Single valve implanted in correct position	24 (100.0)
Conversion to open heart surgery	0 (0.0)
Coronary obstruction	0 (0.0)
New pericardial effusion	0 (0.0)
Major vascular complications	1 (4.2)
Major access-related complications	0 (0.0)
Procedural death	0 (0.0)

	At 30 Days (n = 23)
VARC-3 device success at 30 days [a]	20 (87.0)
Early safety at 30 days [b]	17 (73.9)[c]
Moderate PVL	1 (4.3)[d]
Aortic peak velocity ≥3 m/s	1 (4.3)
Aortic mean gradient ≥20 mmHg	2 (8.7)
All-cause death	0 (0.0)
All stroke	0 (0.0)
Myocardial infarction	0 (0.0)
Cardiovascular hospitalizations	0 (0.0)
VARC type ≥2 bleeding	1 (4.3)
Major vascular complications	1 (4.3)
Major access-related complications	0 (0.0)
Acute kidney injury	0 (0.0)
Clinically significant valve thrombosis	0 (0.0)
New permanent pacemaker implantation	4 (17.4)[e]

Venus-PowerX FIM Clinical Results

- **Valve function improved significantly**
- **30-days follow-up：>95%≤ mild AR；6-month and 1-year follow-up： “0”≥moderate AR**







Venus-PowerX Global Strategy

Global Clinical & Registration Strategy

- EFS completed in Jan 2024, with patients in follow-up
- Global pivotal clinical study is expected to begin in 2H 2024



PowerX Global

- Europe ≈40%
- China ≈60%
- Global Enrollment

150

Cardiovalve

Feature & Clinical Progress

- Fits both MR & TR
- Dual frame self-expanding nitinol, less PVL
- Low ventricular profile, less risk of LVOT obstruction
- Transfemoral-transseptal approach, less damage

  comparing with transapical approach
- Target CE pivotal clinical study for TR has been

  initiated in Nov 2022



Cardiovalve for Mitral and Tricuspid

No radial forces
Proprietary anchoring

Reduce risk for LVOT obstruction

PVL sealing
with inflatable cuff solution

Transfemoral-Transseptal approach

Fits different anatomies, up to 55mm
Vast range of sizes (M,L,XL)

Cardiovalve Tricuspid Compassionate Use Data

- **All patients are functional severe TR; inoperable and suboptimal TEER candidates**
- **High technical success for valve implantation**

Baseline Characteristics （N=20）

Age (Years)	79±6	**TR Etiology**:	100% FTR
NYHA III/IV (%)	12 (60)	Severe TR (%)	2 (10)
Atrial Fibrillation(%)	19 (95)	Massive (%) Torrential (%)	8 (40) 10 (50)
Prior cardiovascular surgery (%)	6 （30）	**LVEF** (%)	49
Prior HF Hospitalizations in past year(%)	10(50)	**GRF**<45 (%)	8 (40)

Procedure Success

Technical Success （%）	90% （18）
Procedure Time (min) (Avg; Min, Max)	83 (30,125)

30-Day Clinical Outcome （N=20）

***Mortality**	10% （2）	**Reintervention**	5% （1）
PPM	10% （2）	**Bleeding**	20% （4）
HF re-hospitalizaitons	5% （1）	**Dialysis**	5% （1）

**None of the death was device related

Refrerece：Transcatheter Tricuspid Valve Replacement with the Cardiovalve system, JACC Cardiovascular Interventions 2024

Cardiovalve Tricuspid Compassionate Use Data

- **Pre-operation： 100% patients ≥ Severe Regurgitation**
- **30-Days follow-up： 95% of patients TR reduced with TR grade ≤1**



*Core Lab Assessment

Reference：Transcatheter Tricuspid Valve Replacement with the Cardiovalve system, JACC Cardiovascular Interventions 2024

Cardiovalve Global Strategy

TARGET STUDY

TR – Global Strategy

- TARGET CE pivotal study has been initiated in Nov 2022
- Multi-Country including Europe and Canada
- As of April 30， enrolled 70+ patients
- Support both CE Mark and China NMPA approval

ONE DATABASE

EU
CE MDR

+

China
NMPA

TARGET Study Sites

Germany

- ukb universitäts klinikumbonn
- UNIKLINIK KÖLN
- UKSH Lübeck UNIVERSITÄTSKLINIKUM Schleswig-Holstein
- UKSH Keil UNIVERSITÄTSKLINIKUM Schleswig-Holstein
- CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN
- Universitäres Herz- und Gefäßzentrum UKE Hamburg
- HDZ NRW UKRUB UNIVERSITÄTSKLINIKUM DER RUHR-UNIVERSITÄT BOCHUM
- Uniklinikum Erlangen
- UNIVERSITÄTSMEDIZIN DRESDEN Universitätsklinikum Carl Gustav Carus Herzzentrum Dresden

Spain

- SERVIZO GALEGO de SAÚDE | Xerencia de Xestión Integrada de Vigo Vigo
- Hospital Universitario Ramón y Cajal
- Clínic Barcelona
- HOSPITAL DE LA SANTA CREU I SANT PAU UNIVERSITAT AUTÒNOMA DE BARCELONA
- HC UV HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID

Canada

- ST. MICHAEL'S UNITY HEALTH TORONTO
- MONTREAL HEART INSTITUTE FOUNDATION
- STpaul's HOSPITAL & HEALTH CAMPUS

Italy

- I.R.C.C.S. Ospedale Galeazzi - Sant'Ambrogio Gruppo San Donato
- Centro Cardiologico Monzino
- OSPEDALE SAN RAFFAELE
- Gruppo San Donato
- Fondazione Monasterio la ricerca che cura | Ospedale del Cuore Massa
- HISI

Epidemiology of Tricuspid Valve Diseases

Tricuspid valve is regarded as “the forgotten valve”, indicating huge patient number and market size

It’s estimated that number of patients with tricuspid valve regurgitation worldwide will achieve 60 million by year 2030, with an incidence case of 200-300 thousand in EU, US respectively.

Tricuspid valve regurgitation has high incidence rate and severe patients’ mortality rate is 36% in 1 year and 48% in 5 years.

The market value of tricuspid valve therapies expected to reach **USD $ 10 billion** in 2030



Sources: 1. Prevalence of moderate-to-severe TR suitable for percutaneous intervention in TTE patients; Z H Teoh, J Roy, J Reiken, M Papitsas, J Byrne, and M J Monaghan; Published online 2018 Oct 29. doi: 10.1530/ERP-18-0018; National Library of Medicine

2. Argarwal et al. Circ Cardiovasc Interv 2009;2:565-573

3.Stuge O, Liddicoat J. J Thorac Cardiovasc Surg. 2006 Dec;132(6):1258-61

RDN Ultrasound Ablation

Venus Medtech formed a joint venture company with Healium Medical Ltd. to introduce next-generation ultrasound ablation technology. The product is under animal experiment

- Precise Power Delivery
- No tissue Contact
- Real Time Monitoring

03 Future Prospects

Outlook of 2024

Cardiovalve
To complete TARGET pivotal study patients enrollment

Launch in **2027**

VenusP-Valve
To initiate the Pivotal Study in U.S.

Launch in **2027**

Venus-Vitae
To initiate the global pivotal study

Launch in **2027**

Venus-PowerX
To initiate the global pivotal study

Launch in **2027**

AR valve RDN
Preparing FIM

Launch in **2028**

4+ products expected to approved by 2027

Outlook of Overseas Sales

Our Mission & Vision

To be a global leader
in structural heart

Overseas sales proportion will increase with innovative products enter harvest period

2023	14.9%
2025	15%
2028	40%

Thanks!